Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

Revises 2008 Financial Guidance

New Launches Should Contribute Significantly in Second Half

WOODCLIFF LAKE, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced results for the second quarter ended June 28, 2008.

Second Quarter and Six Month Results

For the second quarter ended June 28, 2008, Par reported total revenues of $112.9 million and a net loss of $20.1 million, or $0.60 per diluted share. This is compared with reported revenues of $167.6 and net income of $2.8 million, or $0.08 per diluted share, for the same period in 2007. For the six months ended June 28, 2008, Par reported total revenues of $267.9 million and a net loss of $17.5 million, or $0.53 per diluted share. This is compared with reported revenues of $401.9 million and net income of $44.3 million, or $1.27 per diluted share, for 2007.

Patrick G. LePore, chairman, president and chief executive officer of Par said, "Contributing to the Company's disappointing financial results in the second quarter was the lack of new product launches, which is the life-line of the U.S. generics industry. However, I am still confident in our strategy and the outlook for the remainder of 2008 and beyond." Mr. LePore continued, "Our third quarter launches of dronabinol and meclizine, potential additional launches later in the year, strong pipeline of first-to-file products, and progress made in building Strativa's portfolio of innovative branded products positions the Company for long term success."

Second Quarter Financial Review

For the second quarter ended June 28, 2008, total revenues decreased 32.6% compared with the same period a year earlier as a result of increased
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Feb. 25 The International,Confocal Microscopy Working ... students, has been formed as a means ... reflective confocal microscopy (RCM) in,patient care., ... new members worldwide.,Dermatologists, dermascopists, dermatopathologists, medical students ...
... MONTVALE, N.J., Feb. 25 Barr Pharmaceuticals,Inc. ... its subsidiary, Duramed,Pharmaceuticals, Inc., has received notification ... has accepted for review its New Drug ... 0.10,mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... (OTC Bulletin Board: NILT.OB), a biopharmaceutical company focused ... announce the,appointment of Hsiao Dee Lieu, M.D., F.A.C.C. ... am delighted to welcome Dr. Lieu to Nile. ... should be immediately,beneficial to Nile and our CD-NP ...
Cached Biology Technology:International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 3Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 4Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 2Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 3
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... think they have solved an interesting problem: how to ... and complete vegetable protein. What,s more, they,ve joined forces ... soy snack they,ve developed into the hands of 1.2 ... the country has decidedly vegetarian tastes, the Indian people ...
... sensor that may revolutionize how drugs and medical devices are ... the survival of two species of threatened animals. To ... frog. In the wild, the African clawed frog produces ... its skin to protect it from infection. Princeton researchers have ...
... at Yale School of Medicine have found that new ... to Type 1 Gaucher disease, a rare genetic disorder ... resulting in liver/spleen enlargement, osteoporosis, bone pain, and increased ... new findings could lead to less expensive and more ...
Cached Biology News:Illinois scientists promote soy by currying favor with Indian taste buds 2New sensor derived from frogs may help fight bacteria and save wildlife 2New sensor derived from frogs may help fight bacteria and save wildlife 3Cheaper, more effective treatment of type 1 Gaucher disease possible 2
...
... Immunogen: Synthetic peptide derived from ... rat mouse dog and orangutang occludin ... human occludin protein. Reactivity: Human ... Reactivity with rat mouse dog and ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: